Gene Expression in Patients With Advanced or Metastatic Colorectal Cancer Receiving Bevacizumab
This trial is active, not recruiting.
|Treatments||gene expression analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, immunoenzyme technique, immunohistochemistry staining method, immunologic technique|
|Sponsor||Eastern Cooperative Oncology Group|
|Collaborator||National Cancer Institute (NCI)|
|Start date||July 2007|
|Trial size||200 participants|
|Trial identifier||NCT00897754, CDR0000560986, ECOG-E3200T2|
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors understand how patients respond to treatment.
PURPOSE: This laboratory study is looking at gene expression in patients with advanced or metastatic colorectal cancer receiving bevacizumab.
Mean scores for VEGFb and pan-VEGF gene expression by IHC
Comparison of outcome of bevacizumab treatment for groups on either side of the median split of VEGFb:pan-VEGF expression ratios
Gene expression as measured by tissue microarrays
Splice form expression as measured by reverse transcriptase-PCR
VEGF165b protein expression as measured by ELISA
Male or female participants at least 18 years old.
DISEASE CHARACTERISTICS: - Tumor tissue samples available from patients with advanced or metastatic adenocarcinoma of the colon or rectum - Receiving bevacizumab on clinical trial E-3200 PATIENT CHARACTERISTICS: - Not specified PRIOR CONCURRENT THERAPY: - See Disease Characteristics
|Official title||Alternative Splice Forms of VEGF in Colorectal Cancer - Possible Value in Anti-VEGF Therapy|
|Description||OBJECTIVES: - Determine whether the balance of splice form expression alters susceptibility of tumors in vivo to respond to anti-VEGF therapy. OUTLINE: Tumor tissue samples collected on clinical trial E-3200 are analyzed for laboratory endpoints.|
Call for more information